Methazolamide - CAS 554-57-4
Catalog number: 554-57-4
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C5H8N4O3S2
Molecular Weight:
236.27
COA:
Inquire
Targets:
Carbonic Anhydrase
Description:
Methazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
CL 8490
MSDS:
Inquire
1.Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
Del Prete S1, Vullo D2, De Luca V3, Carginale V3, Ferraroni M2, Osman SM4, AlOthman Z4, Supuran CT5, Capasso C6. Bioorg Med Chem. 2016 Mar 1;24(5):1115-20. doi: 10.1016/j.bmc.2016.01.037. Epub 2016 Jan 22.
The genome of the pathogenic bacterium Vibrio cholerae encodes for three carbonic anhydrases (CAs, EC 4.2.1.1) belonging to the α-, β- and γ-classes. VchCA, the α-CA from this species was investigated earlier, whereas the β-class enzyme, VchCAβ was recently cloned, characterized kinetically and its X-ray crystal structure reported by this group. Here we report an inhibition study with sulfonamides and one sulfamate of this enzyme. The best VchCAβ inhibitors were deacetylated acetazolamide and methazolamide and hydrochlorothiazide, which showed inhibition constants of 68.2-87.0nM. Other compounds, with medium potency against VchCAβ, (KIs in the range of 275-463nM), were sulfanilamide, metanilamide, sulthiame and saccharin whereas the clinically used agents such as acetazolamide, methazolamide, ethoxzolamide, dorzolamide, zonisamide and celecoxib were micromolar inhibitors (KIs in the range of 4.51-8.57μM). Identification of potent and possibly selective inhibitors of VchCA and VchCAβ over the human CA isoforms, may lead to pharmacological tools useful for understanding the physiological role(s) of this under-investigated enzymes.
2.The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain.
Fossati S1, Giannoni P2, Solesio ME2, Cocklin SL2, Cabrera E2, Ghiso J3, Rostagno A4. Neurobiol Dis. 2016 Feb;86:29-40. doi: 10.1016/j.nbd.2015.11.006. Epub 2015 Nov 12.
Mitochondrial dysfunction has been recognized as an early event in Alzheimer's disease (AD) pathology, preceding and inducing neurodegeneration and memory loss. The presence of cytochrome c (CytC) released from the mitochondria into the cytoplasm is often detected after acute or chronic neurodegenerative insults, including AD. The carbonic anhydrase inhibitor (CAI) methazolamide (MTZ) was identified among a library of drugs as an inhibitor of CytC release and proved to be neuroprotective in Huntington's disease and stroke models. Here, using neuronal and glial cell cultures, in addition to an acute model of amyloid beta (Aβ) toxicity, which replicates by intra-hippocampal injection the consequences of interstitial and cellular accumulation of Aβ, we analyzed the effects of MTZ on neuronal and glial degeneration induced by the Alzheimer's amyloid. MTZ prevented DNA fragmentation, CytC release and activation of caspase 9 and caspase 3 induced by Aβ in neuronal and glial cells in culture through the inhibition of mitochondrial hydrogen peroxide production.
3.Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.
Supuran CT1. Expert Opin Drug Metab Toxicol. 2016 Apr;12(4):423-31. doi: 10.1517/17425255.2016.1154534. Epub 2016 Mar 3.
INTRODUCTION: Carbonic anhydrase inhibitors (CAIs) of the sulfonamide and sulfamate type are clinically used drugs as diuretics, antiglaucoma, antiepileptic, antiobesity and anti-high altitude disease agents. Anticancer agents based on CAIs are also in clinical development for the management of hypoxic, metastatic tumors. Acetazolamide, methazolamide, dichlorophenamide, dorzolamide and brinzolamide are mainly used as antiglaucoma drugs, sulthiame, topiramate and zonisamide as antiepileptic/antiobesity agents, celecoxib and polmacoxib are dual carbonic anhydrase/cycloxygenase inhibitors. Girentuximab, a monoclonal antibody and SLC-0111, a sulfonamide inhibitor, are in clinical trials as anticancer agents.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Carbonic Anhydrase Products


CAS 554-57-4 Methazolamide

Methazolamide
(CAS: 554-57-4)

Methazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively.

CAS 59-66-5 Acetazolamide

Acetazolamide
(CAS: 59-66-5)

Acetazolamideis a carbonic anhydrase inhibitor used to treat glaucoma.

CAS 138890-62-7 Brinzolamide

Brinzolamide
(CAS: 138890-62-7)

Brinzolamide is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.

CAS 178606-66-1 SLC-0111

SLC-0111
(CAS: 178606-66-1)

SLC-0111, also known as U-104, MST-104 and NSC 213841, is a potent carbonic anhydrase (CA) inhibitor (Ki values are 4.5, 45.1, 5080 and 9640 nM for CA XII, CA I...

CAS 120-97-8 Dichlorphenamide

Dichlorphenamide
(CAS: 120-97-8)

Dichlorphenamide is a sulfonamide and a carbonic anhydrase inhibitor of the meta-Disulfamoylbenzene class.

CAS 73-49-4 quinethazone

quinethazone
(CAS: 73-49-4)

Quinethazone is a thiazide-like diuretic. It is a carbonic anhydrase inhibitor and can be used for the treatment of hypertension.

CAS 4991-65-5 Tioxolone

Tioxolone
(CAS: 4991-65-5)

Tioxolone is a metalloenzyme carbonic anhydrase I inhibitor with a Ki of 91 nM.

Chemical Structure

CAS 554-57-4 Methazolamide

Quick Inquiry

Verification code

Featured Items